Liquidia Corporation (LQDA) key performance indicators and operating metrics (18 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Prescription-to-patient-start conversion rate | 85.00 percent | FY2026-Q2 |
| YUTREPIA prescribers | 1.1K | FY2026-Q2 |
| Patients started on YUTREPIA | 3.75K | FY2026-Q1 |
| YUTREPIA share of inhaled treprostinil market | 30.00 percent | FY2026-Q2 |
| YUTREPIA net product sales | 170.38M | FY2026-Q2 |
| Net product sales growth | 31.00 percent | FY2026-Q2 |
| Unique patient prescriptions | 5.9K | FY2026-Q2 |
| Prescribers with five or more YUTREPIA patients | 30.00 percent | FY2026-Q2 |
| Inhaled prostacyclin market growth | 6.00 percent | FY2026-Q2 |
| Inhaled treprostinil market net revenue | 607M | FY2026-Q2 |
| Naive patient share of starts | 75.00 percent | FY2026-Q1 |
| Transition patient share of starts | 25.00 percent | FY2026-Q1 |
| Net service revenue | 1.3M | FY2026-Q2 |
| Adjusted EBITDA | 96.29M | FY2026-Q2 |
Back to LQDA overview · LQDA earnings · LQDA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.